Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1061-1070

  Zhao, Bai ^a   Sun, Tiemin ^b   Meng, Fanjuan ^b   Qu, Aibing ^b   Li, Chunling ^b   Shen, Hui ^b   Jin, Yu ^b   Li, Wenxin ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Tumor Hospital of Liaoning Province   (China)

Author keywords

Invasiveness; Lung cancer; OPN; Proliferation

Indexed keywords

BROXURIDINE; LENTIVIRUS VECTOR; MATRIGEL; OSTEOPONTIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HEK293; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SPLICING DEFECT;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; OSTEOPONTIN; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79956373316     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0968-7     Document Type: Article

References (27)

1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-521 (Pubitemid 34411290)
2. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453-457 (Pubitemid 43080020)
3. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12:3337-3343
4. Campbell TN, Choy FY (2005) RNA interference: past, present and future. Curr Issues Mol Biol 7:1-6 (Pubitemid 39561787)
5. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311-323
6. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 43:225-236
7. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184-190
8. Ehrchen J, Heuer H, Sigmund R, Schafer MK, Bauer K (2001) Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169:87-96 (Pubitemid 32273218)
9. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5:1516-1523
10. Inman CK, Shore P (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684-48689 (Pubitemid 41079508)
11. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y (2006) An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 12:1308-1316 (Pubitemid 43342523)
12. Jessen KA, Liu SY, Tepper CG, Karrim J, McGoldrick ET, Rosner A, Munn RJ, Young LJ, Borowsky AD, Cardiff RD, Gregg JP (2004) Molecular analysis ofmetastasis in a polyomavirus middle Tmouse model: the role of osteopontin. Breast Cancer Res 6:157-169
13. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671-1679 (Pubitemid 34289219)
14. Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90:986-992 (Pubitemid 38008022)
15. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF (2008) Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122:889-897
16. Nagatomo T, Ohga S, Takada H, Nomura A, Hikino S (2004) Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol 138:47-53 (Pubitemid 39279964)
17. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427 (Pubitemid 34651388)
18. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123-133 (Pubitemid 44440172)
19. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11:279-303
20. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361-6371 (Pubitemid 47494216)
21. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277 (Pubitemid 29399287)
22. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mamm Gland Biol Neoplasia 6:419-429
23. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578-584 (Pubitemid 27259939)
24. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 9:127-132 (Pubitemid 28201682)
25. Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 121:228-241 (Pubitemid 39387464)
26. Wang Y, Yang H, Liu H, Huang J, Song X (2009) Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer 9:174
27. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61-85